Retinoic Acid Receptor-beta Expression in Stage I Non-Small Cell Lung Cancer and Adjacent Normal Appearing Bronchial Epithelium.
10.3349/ymj.2004.45.3.435
- Author:
Yoon Soo CHANG
1
;
Jae Ho CHUNG
;
Dong Hwan SHIN
;
Kyung Young CHUNG
;
Young Sam KIM
;
Joon CHANG
;
Sung Kyu KIM
;
Se Kyu KIM
Author Information
1. Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. sekyukim@yumc.yonsei.ac.kr.
- Publication Type:Original Article
- Keywords:
Biomarker;
chemoprevention;
retinoic acids;
retinoic acid receptor-beta;
non-small cell lung cancer
- MeSH:
Adult;
Aged;
Bronchi/metabolism/pathology;
Carcinoma, Non-Small-Cell Lung/*metabolism/pathology;
Down-Regulation;
Female;
Human;
Immunohistochemistry;
Lung Neoplasms/*metabolism/pathology;
Male;
Middle Aged;
Neoplasm Staging;
Receptors, Retinoic Acid/*metabolism;
Respiratory Mucosa/*pathology;
Tumor Markers, Biological/*metabolism
- From:Yonsei Medical Journal
2004;45(3):435-442
- CountryRepublic of Korea
- Language:English
-
Abstract:
Retinoic acid receptor- (RAR-beta) is induced by and mediates the growth-inhibitory and apoptotic effects of retinoic acid (RA), suggesting that loss of RAR-betaexpression may be one of the critical events involved in the carcinogenesis/ progression of non-small cell lung cancer (NSCLC) and in the responsiveness to retinoid chemotherapy. However, recent contradictory reports that the expression of RAR-beta is associated with poor clinical outcome, and the fact that treatment of serum-deprived type 2 alveolar cells with RA leads to a stimulation of cell proliferation, require the verification of RAR-beta as a biomarker of chemoprevention or prognosis. The expression status of RAR-beta in cancer cells and adjacent normal appearing bronchial epithelium from 39 patients, diagnosed as stage I NSCLC and undergone a curative lung resection, was analyzed in paraffin-embedded tissue sections by IHC staining. The normal appearing bronchial epithelium of 14 out of 33 (42.4%) specimens expressed RAR-beta, whereas 22 out of the 39 (56.4%) stage I NSCLC specimens expressed RAR-beta. RAR-beta was more frequently expressed in the adenocarcinoma (72.7%) than in the squamous cell carcinoma (31.3%) (p=0.026). Neither the expression status in normal appearing adjacent tissue nor that in the tumor tissue had prognostic implications. The higher expression of RAR-beta in cancer tissue, the focal and uneven distribution in normal appearing adjacent bronchial epithelium, and inconsistency with the corresponding tumor tissue, suggest that the expression status of RAR-beta as a biomarker for chemoprevention/early diagnosis or the prognosis of NSCLC requires further consideration.
